Investing In Clinical Trial Site Management Organizations, CROs and Research Technology Vendors: Key Regulatory and Diligence Considerations - McDermott Will & Emery

Investing In Clinical Trial Site Management Organizations, CROs and Research Technology Vendors: Key Regulatory and Diligence Considerations

Overview



The pharma services space is abuzz with activity as funding rebounds, R&D activity grows and technology accelerates innovation. Clinical trial site management organizations (CTSMOs), contract research organizations (CROs) and research technology vendors play a key role in the conduct, acceleration and digitization of clinical research in the life sciences industry.

By deploying innovative methods in subject recruitment and using tech-enabled solutions to create more efficient, scalable and sophisticated platforms for the conduct and oversight of clinical research, they present myriad opportunities for investors to add value and expand their portfolios. However, this highly regulated space requires specialized due diligence to ensure success.

During this webinar, our global team discussed:

  • Trends behind the growth in CTSMOs, CROs and research technology vendors.
  • The range of organizations and vendors that conduct and support research on behalf of the life sciences industry.
  • The PE perspective, including what organizations should watch out for when acquiring and investing.
  • The importance of bringing in policy specialists during post-closing for gap assessments.

Investing in pharma services can be complicated, but our team will ensure you’re asking the right questions during the diligence process.

Dig Deeper

Nashville, TN / McDermott Event / May 6-9, 2025

McDermott HealthEx

Paris, France / McDermott Event / April 2, 2025

European Health & Life Sciences Symposium 2025

Miami, FL / McDermott Event / March 5-6, 2025

HPE Miami 2025

San Francisco, CA / McDermott Event / January 14, 2024

McDermott Forum During the 2025 J.P. Morgan Healthcare Conference

Get In Touch